1. Therapeutic implication of targeting mitochondrial drugs designed for efferocytosis dysfunction.
- Author
-
Liu, Wan-Ting, Li, Chao-Quan, Fu, Ao-Ni, Yang, Hao-Tian, Xie, Yu-Xin, Yao, Hui, and Yi, Guang-Hui
- Subjects
- *
MITOCHONDRIAL dynamics , *MITOCHONDRIAL pathology , *DRUG design , *AUTOIMMUNE diseases , *IMMUNE system - Abstract
Efferocytosis refers to the process by which phagocytes remove apoptotic cells and related apoptotic products. It is essential for the growth and development of the body, the repair of damaged or inflamed tissues, and the balance of the immune system. Damaged efferocytosis will cause a variety of chronic inflammation and immune system diseases. Many studies show that efferocytosis is a process mediated by mitochondria. Mitochondrial metabolism, mitochondrial dynamics, and communication between mitochondria and other organelles can all affect phagocytes' clearance of apoptotic cells. Therefore, targeting mitochondria to modulate phagocyte efferocytosis is an anticipated strategy to prevent and treat chronic inflammatory diseases and autoimmune diseases. In this review, we introduced the mechanism of efferocytosis and the pivoted role of mitochondria in efferocytosis. In addition, we focused on the therapeutic implication of drugs targeting mitochondria in diseases related to efferocytosis dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF